[Pharmacokinetics of cefmenoxime in renal-failure patients undergoing continuous arteriovenous hemofiltration]

Jpn J Antibiot. 1988 Mar;41(3):338-41.
[Article in Japanese]

Abstract

We investigated the pharmacokinetics of cefmenoxime (CMX) administrated to renal-failure patients undergoing continuous arteriovenous hemofiltration (CAVH). CAVH was carried out with a filter (0.5 m2) employing a PAN-50P (hollow fiber type) made of polyacrylonitrile membrane, with a blood flow rate of 100 ml/min and a filtration rate of 1,200 ml/hr. At 5 and 300 minutes after the CMX administration, the concentrations of CMX in the serum were 126.8 mg/L and 31.5 mg/L, respectively. The T1/2 beta was 3.55 hours. In 300 minutes after the administration of CMX, the total amount of CMX contained in the filtrate corresponded to 11.6% of the administered dose.

Publication types

  • English Abstract

MeSH terms

  • Acute Kidney Injury / metabolism*
  • Acute Kidney Injury / therapy
  • Adult
  • Aged
  • Cefmenoxime
  • Cefotaxime / administration & dosage
  • Cefotaxime / analogs & derivatives*
  • Cefotaxime / blood
  • Cefotaxime / pharmacokinetics
  • Hemofiltration*
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged

Substances

  • Cefmenoxime
  • Cefotaxime